Practical considerations in development of solid dosage forms that contain cyclodextrin.
The following is a review of the literature that addresses the use of cyclodextrin in solid dosage forms. Care was taken to exclude physical and chemical characteristics of cyclodextrin, which have been discussed in the literature. A flow diagram is provided to outline the decision-making steps that are involved in the development process. Both preparation of physical mixtures and inclusion complexes are considered. Analytical techniques to determine the presence of inclusion complexes, the effect of other excipients on complex formation, the effect of size limitation of solid dosages forms, powder processing, and storage of solid dosage forms are discussed.
Miller
Lee A
LA
Pfizer, Inc., Ann Arbor, Michigan 48105, USA. lee.a.miller@pfizer.com
Carrier
Rebecca L
RL
Ahmed
Imran
I
D000465:Algorithms; D002626:Chemistry, Pharmaceutical; D003505:Cyclodextrins / Q000737:chemistry*; D004304:Dosage Forms; D004337:Drug Carriers; D004339:Drug Compounding; D004355:Drug Stability; D004356:Drug Storage; D005079:Excipients / Q000737:chemistry; D008956:Models, Chemical; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011208:Powders; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods*
D003505:Cyclodextrins; D004304:Dosage Forms; D004337:Drug Carriers; D005079:Excipients; D004364:Pharmaceutical Preparations; D011208:Powders